Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 4/20 | 0.46 |
| ▸ | CDK8 | P49336 | 4/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | WNT1 | P04628 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30845793 | 0.87 | CCNC (0.48) | CCNCCDK8PIM1PIM2FGFR2 | |
| SCHEMBL21033491 | 0.82 | KDM4E (0.55) | CHEK1FGFR2FGFR3FGFR1FGFR4 | |
| SCHEMBL21033166 | 0.79 | USP30 (0.55) | CCNCCDK8PIM1PIM2CHEK1 | |
| SCHEMBL23534294 | 0.79 | PORCN (0.38) | ABL1 | |
| SCHEMBL3500124 | 0.77 | GRM5 (0.53) | MAP4K4 | |
| SCHEMBL21033208 | 0.77 | PIK3C3 (0.40) | — | |
| SCHEMBL2108962 | 0.76 | CCNC (0.56) | CCNCCDK8PIM1PIM2CHEK1 | |
| SCHEMBL23553891 | 0.75 | RXFP1 (0.43) | — | |
| SCHEMBL21033340 | 0.75 | CHEK1 (0.47) | CCNCCDK8PIM1PIM2CHEK1 | |
| SCHEMBL23571979 | 0.73 | PTGS1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC | 2021-12-02 | — | — | US | disclosed |
| WO-2019102494-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | CCNC 1286/4885CDK8 273/4885PIM1 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.